Nesvategrast is under clinical development by OcuTerra Therapeutics and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nesvategrast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nesvategrast is under development for the treatment of wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, moderate to severe non-proliferative and mild proliferative diabetic retinopathy. The drug candidate is administered topically. SF-0166 acts by targeting integrin alpha v beta 3. The drug candidate is developed based on the fluorine-centered approach.
OcuTerra Therapeutics overview
OcuTerra Therapeutics (OcuTerra), formerly SciFluor Life Sciences, is an ophthalmology company that strives to develop drugs for eye diseases. It is investigating OTT166, a small molecule integrin inhibitor eye drop solution that targets non-proliferative and proliferative diabetic retinopathy and other ocular diseases. The company’s approach focuses on blocking integrin aVß3 and regulating VEGF (vascular endothelial growth factor) and other multiple growth factors responsible for new blood vessel growth (angiogenesis) and vascular leakage (macular edema). OcuTerra is headquartered in Boston, Massachusetts, the US.
For a complete picture of Nesvategrast’s drug-specific PTSR and LoA scores, buy the report here.